Investigation of the Expression Levels of miR-155, miR-133a, and miR-146b in the Serum of Acute and Chronic Forms of Cutaneous Leishmaniasis
- PMID: 40828401
- DOI: 10.1007/s11686-025-01123-x
Investigation of the Expression Levels of miR-155, miR-133a, and miR-146b in the Serum of Acute and Chronic Forms of Cutaneous Leishmaniasis
Abstract
Background: Leishmaniasis is a vector-borne infectious disease caused by intracellular protozoan parasites of the genus Leishmania. MicroRNAs (miRNAs) can influence the progress and outcome of the disease. This study aimed to investigate the expression levels of miR-155, miR-133a, and miR-146b in the serum of acute and chronic forms of cutaneous leishmaniasis (CL) in Iran.
Methods: Samples were collected from 30 clinical cases of CL in Golestan province, who suffered from either acute or chronic forms of the disease, including 15 for each. Leishmania species were identified using PCR (kDNA gene). Total RNA was extracted from serum samples, complementary DNA (cDNA) was synthesized based on the loop technique, and the expression levels of miRNAs (miR-155, miR-133a, and miR-146b) were determined through quantitative real-time PCR analysis.
Results: Conventional PCR on kDNA confirmed the presence of L. major in 30 patients. Healing after one course of treatment and no response to treatment were considered as acute and chronic forms, respectively. Although there were no statistically significant changes, the expression of miR-133a and miR-155 was upregulated in patients with acute CL compared to those with chronic form, while miR-146b was downregulated in patients with acute CL.
Conclusions: In the current study, the expression changes of miR-155, miR-146b, and miR-133a in acute patients was compared to those patients with chronic CL. Although it was not significant, alterations in the expression levels of miRNAs were observed between acute and chronic forms of CL suggesting different pathogenesis of clinical forms.
Keywords: Leishmania major; Cutaneous leishmaniasis; Iran; MiR-133a; MiR-146b; MiR-155.
© 2025. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Conflict of interest statement
Declarations. Ethics Approval: This project was approved by the Ethical Review Committee of the AJA University of Medical Sciences, Tehran, Iran (IR.AJAUMS.REC.1403.227). Competing Interests: The authors declare no competing interests.
Similar articles
-
Interventions for Old World cutaneous leishmaniasis.Cochrane Database Syst Rev. 2017 Dec 1;12(12):CD005067. doi: 10.1002/14651858.CD005067.pub5. Cochrane Database Syst Rev. 2017. PMID: 29192424 Free PMC article.
-
Interventions for Old World cutaneous leishmaniasis.Cochrane Database Syst Rev. 2017 Nov 17;11(11):CD005067. doi: 10.1002/14651858.CD005067.pub4. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2017 Dec 01;12:CD005067. doi: 10.1002/14651858.CD005067.pub5. PMID: 29149474 Free PMC article. Updated.
-
Altered miRNA expression in the lesions of cutaneous leishmaniasis caused by L. major and L. tropica with insights into apoptosis regulation.Sci Rep. 2025 Jul 1;15(1):20680. doi: 10.1038/s41598-025-03802-1. Sci Rep. 2025. PMID: 40594138 Free PMC article.
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Sensitive and Specific Detection/Identification of Leishmania major, Leishmania tropica, and Leishmania infantum by a Single Real Time PCR Targeting Hsp70.Vector Borne Zoonotic Dis. 2025 Aug;25(8):511-516. doi: 10.1089/vbz.2024.0087. Epub 2025 Jun 4. Vector Borne Zoonotic Dis. 2025. PMID: 40464144
References
-
- Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R (2017) Leishmaniasis: a review. F1000 Research 6
-
- Desjeux P (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27(5):305–318 - PubMed
-
- Reithinger R, Dujardin J-C, Louzir H, Pirmez C, Alexander B, Brooker S (2007) Cutaneous leishmaniasis. Lancet Infect Dis 7(9):581–596 - PubMed
-
- Murray HW, Berman JD, Davies CR, Saravia NG (2005) Advances in leishmaniasis. Lancet 366(9496):1561–1577 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources